HIV Binding Agents

Abstract

This disclosure relates to binding agents with specificity for HIV and to methods for using the same to treat, pre-vent and/or ameliorate HIV infection and/or AIDS.

1 . A binding agent that neutralizes HIV in an in vitro HIV neutralization assay and/or in vivo, the binding agent at least one amino acid sequence selected from the group consisting of SEQ ID NOS. 1-32 and/or shown in Table 1. 
     
     
         2 - 17 . cancelled 
     
     
         18 . The binding agent of  claim 1  comprising a conservative substitution of an amino acid residue of any one or more of SEQ ID NOS. 1-32. 
     
     
         19 . The binding agent of  claim 1  derived from a human antibody, human IgG, human IgG1, human IgG2, human IgG2a, human IgG2b, human IgG3, human IgG4, human IgM, human IgA, human IgAl, human IgA2, human IgD, human IgE, canine antibody, canine IgGA, canine IgGB, canine IgGC, canine IgGD, chicken antibody, chicken IgA, chicken IgD, chicken IgE, chicken IgG, chicken IgM, chicken IgY, goat antibody, goat IgG, mouse antibody, mouse IgG, pig antibody, and rat antibody. 
     
     
         20 . A derivative of a binding agent of  claim 1 . 
     
     
         21 . The derivative of  claim 20  selected from the group consisting of an F ab , F ab2 , Fab′ single chain antibody, F v , single chain, mono-specific antibody, bispecific antibody, trimeric antibody, multi-specific antibody, multivalent antibody, chimeric antibody, canine-human chimeric antibody, canine-mouse chimeric antibody, antibody comprising a canine Fc, humanized antibody, human antibody, caninized antibody, CDR-grafted antibody, shark antibody, nanobody, and canelid antibody. 
     
     
         22 - 26 . canceled 
     
     
         27 . An isolated polynucleotide encoding a binding agent of  claim 1 . 
     
     
         28 . The isolated polynucleotide of  claim 28  comprising a nucleic acid sequence of at least one of SEQ ID NOS. 37-72. 
     
     
         29 . An expression vector comprising one or more polynucleotides of  claim 27 . 
     
     
         30 . A host cell comprising the isolated polynucleotide of  claim 27 . 
     
     
         31 . A composition comprising at least one binding agent of  claim 1 ; and, a pharmaceutically acceptable carrier. 
     
     
         32 . A method for detecting HIV on a cell, the method comprising contacting a test biological sample with a binding agent of  claim 1  and detecting the binding agent bound to the biological sample or components thereof. 
     
     
         33 . The method of  claim 32 , further comprising comparing the amount of binding to the test biological sample or components thereof to the amount of binding to a control biological sample or components thereof, wherein increased binding to the test biological sample or components thereof relative to the control biological sample or components thereof indicates the presence of a cell expressing HIV in the test biological sample. 
     
     
         34 . The method of  claim 32  wherein the test biological sample is mammalian blood, wherein the method is an in vivo method or an in vitro method. 
     
     
         35 . canceled 
     
     
         36 . canceled 
     
     
         37 . A method for treating, preventing and/or ameliorating HIV infection and/or AIDS in a mammal comprising administering to the mammal at least one effective dose of a pharmaceutical composition comprising a binding agent of  claim 1 . 
     
     
         38 . The method of  claim 37  wherein multiple doses are administered to the animal. 
     
     
         39 . The method of  claim 37  wherein the binding agent is administered in a dosage amount of about 1 to 50 mg/kg. 
     
     
         40 . A kit for detecting the expression of HIV in or on a cell, the kit comprising a binding agent of  claim 1  and instructions for use. 
     
     
         41 . The kit of  claim 40  wherein the binding agent, antibody, or derivative is in lyophilized form.